logoAiPathly

Inari Medical

I

Overview

Inari Medical is a pioneering medical device company dedicated to treating and transforming the lives of patients suffering from venous diseases, with a particular focus on venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Mission and Products

The company's mission centers on improving patient outcomes through innovative devices. Their product portfolio includes:

  • FlowTriever System: A large bore catheter-based aspiration and mechanical thrombectomy system for removing large clots from venous vessels, the right heart, pulmonary arteries, and lungs. FDA-approved for Pulmonary Embolism (PE) treatment in 2018 and Right Atrial Clot in Transit in 2021.
  • ClotTriever System: Designed to core, capture, and remove large clots from large venous vessels. Received FDA 510(k) market clearance in 2017 for non-surgical removal of thrombi and emboli from peripheral vasculature.

Clinical Research and Market Presence

Inari Medical demonstrates a strong commitment to clinical data generation through studies and registries such as FLARE, CLOUT, FLASH, FLAME, and PEERLESS. The company operates in multiple countries, including the US, Switzerland, Singapore, Canada, Australia, Brazil, the UK, and Ireland, with a rapidly expanding sales team. The estimated addressable market in the US alone is $5.8 billion, with significant international opportunities.

Financial Performance and Recent Developments

Since its successful IPO in May 2020, Inari Medical has shown robust quarterly revenue growth with gross margins exceeding 80%. Recent developments include:

  • Securing national reimbursement approval in Japan for the ClotTriever Thrombectomy System (December 2024)
  • Entering a joint venture to introduce devices in Greater China
  • Partnering with the American Venous Forum and the National Blood Clot Alliance on the DEFIANCE trial

Commitment to Healthcare

Inari Medical is dedicated to establishing its treatments as the standard of care for VTE and related conditions through innovative solutions, education, clinical research, and program development. Their ethos, "Patients first. Always," underscores their commitment to improving patient outcomes and transforming lives affected by venous diseases.

Leadership Team

Inari Medical's leadership team comprises experienced professionals driving the company's mission to revolutionize venous disease treatment. Key members include:

Executive Leadership

  • Drew Hykes - Chief Executive Officer (CEO): Assumed the role in January 2023, bringing extensive experience from previous positions at Inari Medical, Medtronic, Sequent Medical, and Terumo.

Financial and Operational Leadership

  • Kevin Strange - Chief Financial Officer: Joined in 2020, progressing from VP of Strategy and Business Development to CFO in 2024.
  • Amna Vugdalic - Vice President, Finance

Clinical and Medical Affairs

  • Thomas Tu - Chief Medical Officer: Oversees medical affairs and clinical initiatives.
  • Dr. Andrew Niekamp - Vice President of Medical Affairs: Joined in 2024, bringing expertise in Vascular Interventional Radiology and clinical research.
  • Vic Tapson - Vice President, Medical Affairs

Marketing and Commercial Operations

  • Eric Khairy - Senior Vice President, Marketing: Leads marketing strategies and commercial operations.
  • Tim Benner - Senior Vice President of U.S. Sales: Joined in 2024 with extensive commercial leadership experience.

Product and Business Unit Leadership

  • Tara Dunn - Senior Vice President & General Manager, LimFlow: Oversees the LimFlow business unit.
  • Shon Chakrabarti, MD MPH - Chief Medical Officer, LimFlow: Focuses on improving outcomes for Chronic Limb Threatening Ischemia (CLTI) patients.

Operations and Strategy

  • Paul Koehn - Senior Vice President, Operations: Responsible for operational efficiency.
  • Shawn Flaherty - Vice President US Strategy & Sales

Quality, Regulatory, and Clinical Affairs

  • Mazi Kiani - Joined in 2024 with over two decades of experience in Quality, Regulatory, and Clinical Affairs.
  • Shannon Trevino - General Counsel and Corporate Secretary: Joined in 2023 with over 15 years of legal experience.

Investor Relations

  • Neil Bhalodkar - Joined in 2024 with extensive experience in investor relations and corporate finance. This diverse leadership team combines expertise in medical devices, finance, clinical research, marketing, and operations to drive Inari Medical's growth and innovation in venous disease treatment.

History

Inari Medical, a pioneering medical device company focused on treating venous diseases, has a compelling history marked by innovation and rapid growth. Key milestones include:

Founding and Early Years

  • Founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator
  • Backed by notable investors including Gilde Healthcare, Versant Ventures, and U.S. Venture Partners

Product Development and FDA Approvals

  • Developed two primary mechanical thrombectomy platforms:
    1. FlowTriever System:
      • FDA approval for Pulmonary Embolism (PE) treatment in May 2018
      • Additional clearance for Right Atrial Clot in Transit in January 2021
    2. ClotTriever System:
      • FDA 510(k) market clearance in February 2017 for non-surgical removal of thrombi and emboli from peripheral vasculature

Market Expansion and Growth

  • Completed Initial Public Offering (IPO) in May 2020, raising $156 million
    • Notable as the first non-biotech IPO post-COVID-19 outbreak
    • Shares performed exceptionally well, closing at $42.51 on the first day of trading
  • Expanded commercial organization in the U.S. and internationally
  • Estimated addressable market of $5.8 billion in the U.S. alone, with significant international opportunities

Clinical Research and Studies

  • Invested heavily in clinical research, including studies and registries such as FLARE, CLOUT, FLASH, FLAME, and PEERLESS
  • Focused on generating real-world evidence to drive device adoption and improve patient outcomes

Recent Developments

  • Secured national reimbursement approval in Japan for the ClotTriever Thrombectomy System (December 2024)
  • Entered joint venture agreement to introduce devices in Greater China (December 2024)
  • Partnered with American Venous Forum and National Blood Clot Alliance on the DEFIANCE trial

Mission and Culture

  • Committed to treating and transforming lives of patients with venous diseases
  • Emphasizes patient-first approach, innovation, and a culture valuing diversity and inclusivity Inari Medical has established itself as a leader in venous thromboembolism treatment, driven by innovative products, robust clinical research, and a steadfast commitment to patient care.

Products & Solutions

Inari Medical Inc. specializes in developing innovative catheter-based technologies for treating venous thromboembolism (VTE). Their key products include:

ClotTriever System

  • Designed for deep vein thrombosis (DVT) treatment
  • Uses mechanical coring, collection, and retrieval of emboli and thrombi
  • Components include ClotTriever Thrombectomy Catheter and associated sheaths

FlowTriever System

  • Treats pulmonary embolism (PE) and other vascular thrombi
  • Employs mechanical and aspirational disruption, fragmentation, maceration, and retrieval
  • Includes various catheters: FlowTriever, FlowTriever2, Triever16, Triever20, and Triever24

Artix Thrombectomy System

  • Dual mechanical and aspiration solution for arterial thrombus cases
  • Features covered funnel catheter and MT thrombectomy device
  • Used for nonsurgical removal of emboli and thrombi

Additional Products

  • Protrieve Sheath: Used with Inari's thrombectomy systems
  • InThrill Sheath and Catheter: Part of the thrombectomy portfolio
  • FlowStasis Suture Retention Device: For suture retention
  • FlowSaver Blood Return System: Enables autologous blood transfusion

Clinical Application

Inari Medical's products are utilized by interventional radiologists, cardiologists, and vascular surgeons in catheterization laboratories and interventional suites for treating conditions like DVT and PE.

Core Technology

Inari Medical's core technology focuses on innovative solutions for venous thromboembolism (VTE) and other venous diseases. Key aspects include:

Mechanical Thrombectomy Devices

  1. FlowTriever System
    • First FDA-cleared mechanical thrombectomy device for pulmonary embolism (PE)
    • Enables single-session, thrombolytic-free removal of thrombi from pulmonary arteries
    • Improves patient hemodynamics without thrombolytic-associated risks
  2. ClotTriever System
    • Treats deep vein thrombosis (DVT)
    • Features atraumatic nitinol coring element and mesh collection bag
    • Extracts large thrombi in a single session without thrombolytics or ICU monitoring
  3. RevCore Thrombectomy Catheter
    • Specifically designed for venous in-stent thrombosis
    • Unique diameter-controlled coring element for safe thrombi engagement within stents
  4. Triever16 Curve Catheter
    • Versatile for both PE and peripheral thrombectomy
    • Pre-shaped curve for targeted aspiration
    • Compatible with FlowSaver blood return system

Key Technologies and Features

  • HyperClear Technology: Reduces clot adhesion in collection bags
  • Nitinol Coring Element and Mesh Collection Bag: Facilitates thrombi removal
  • Self-Expanding Nitinol Funnel: Ensures optimal clot extraction

Clinical Performance

  • High rates of thrombus removal
  • Minimal blood loss
  • Improved patient quality-of-life measures
  • CLOUT registry: 100% thrombus removal in most patients, near-complete removal in 85.2% Inari Medical's technologies aim to provide safe, efficient, and effective VTE treatments, often in a single session without thrombolytics, potentially reducing complications and improving outcomes.

Industry Peers

Inari Medical operates in the medical device industry, specializing in venous and related diseases treatment. Key industry peers and competitors include:

Direct Competitors

  1. Retriever Medical
    • Focus: Vascular disease treatment
    • Products: Aspiration catheters, mechanical thrombectomy devices, blood filtration systems
  2. Ceretrieve Ltd.
    • Specialization: Neurointerventional devices
    • Offerings: Distal access catheters, thrombectomy devices
  3. Imperative Care
    • Focus: Stroke and vascular diseases
    • Solutions: Interventional tools, robotic technologies for thrombectomy
  4. Route 92 Medical
    • Specialization: Neurovascular intervention
    • Key Product: FreeClimb catheter systems

Broader Industry Peers

  1. Penumbra: Neuro and vascular healthcare technologies
  2. Teleflex: Global provider of critical care and surgical medical devices
  3. AngioDynamics: Vascular and oncology medical devices
  4. LeMaitre Vascular: Peripheral vascular disease and cardiovascular disease solutions

Publicly Traded Peers

  1. Boston Scientific Corporation: Wide range of medical devices
  2. LivaNova PLC: Cardiovascular and neuromodulation solutions
  3. iRhythm Technologies, Inc.: Cardiac arrhythmia diagnostic and monitoring devices
  4. QuidelOrtho Corporation: Diagnostic and medical device development and manufacturing These companies operate within the broader medical device and healthcare equipment industry, often targeting similar or adjacent markets to Inari Medical.

More Companies

L

Lambda

AWS Lambda is a serverless compute service offered by Amazon Web Services (AWS) that enables developers to run code without managing servers. Key aspects of AWS Lambda include: Event-Driven Computing: Lambda executes code in response to various triggers or events from AWS services or external sources. Serverless Architecture: Eliminates server management tasks, allowing developers to focus on code while AWS handles infrastructure. Key Features: - Environment Variables: Adjust function behavior without code changes - Versions and Aliases: Manage function deployments - Container Images: Support for larger workloads - Lambda Layers: Package and share libraries - Lambda Extensions: Enhance monitoring, security, and governance - Function URLs: Dedicated HTTP(S) endpoints - Concurrency and Scaling Controls: Fine-tune performance - Code Signing: Verify trusted code - Private Networking: Secure resource access - File System Integration: Mount Amazon EFS - Lambda SnapStart: Achieve sub-second startup times Use Cases: - File processing - Stream processing - Web and mobile application backends - IoT device data handling - Real-time data analysis Pricing Model: Pay-per-request, charging only for consumed compute time. Scalability and Availability: Automatic scaling based on demand, ensuring high availability and performance. Limitations: - Cold start latency - Limited control over infrastructure - Maximum execution time of 15 minutes AWS Lambda enables developers to build scalable, cost-efficient applications while focusing on code rather than infrastructure management.

S

Solera Health

Solera Health is a healthcare company specializing in connecting individuals, particularly those with chronic conditions, to a network of community and digital health solutions. This comprehensive overview highlights key aspects of the company: ### Business Model and Platform Solera Health operates on a unique model that integrates a network of community-based programs and digital health tools. The platform uses data-driven algorithms to match individuals with vetted, evidence-based programs tailored to their specific needs, preferences, and health goals. ### Services and Solutions - Community Health Solutions: Partnerships with local organizations to offer a wide range of health programs, including nutrition, fitness, mental health, and chronic disease management. - Digital Health Tools: Access to mobile apps, online coaching services, and virtual support groups. - Personalized Support: Assistance in finding resources that best fit users' goals and lifestyles. ### Target Customers and Market Footprint - Primary customers: Health plans and employers, including Blue Shield of California, Anthem Blue Cross Blue Shield, and Blue Cross Blue Shield of Kansas City. - Market reach: Network spans over 11,000 local programs, covering more than 40 million lives across 50 states, with over 15 enterprise customers. ### Partnerships and Collaborations Solera Health collaborates with partners such as FitBit, Blue Cross Blue Shield Institute, and US Preventive Medicine to expand its network and enhance offerings. ### Revenue Generation and Pricing Model The company uses an outcomes-based billing model with performance-based contracts tied to specific health outcomes. Payments are made through medical claims or value-based invoice payments. ### Key Features and Benefits - Data-Driven Matching: Advanced algorithms match individuals with appropriate health programs. - Centralized Hub: A single platform for accessing various health and wellness resources. - Improved Health Outcomes: Reported improvements in healthier food choices, weight loss, and increased physical activity among participants. ### Leadership and Funding - Founded in 2015 and headquartered in Phoenix, AZ. - Leadership team includes Brenda Schmidt (CEO & Founder), Ian Gordon (President & COO), Sandeep Wadhwa, MD (Chief Health Officer & SVP, Market Innovation), and Rick Smith (CFO). - Received $72.3 million in funding from investors such as Blue Cross Blue Shield Ventures/Sandbox Industries, Adams Street Partners, and HCSC Ventures. Solera Health aims to make healthcare more accessible, affordable, and effective by connecting individuals with diverse health solutions, thereby improving outcomes and reducing healthcare costs.

L

LanzaTech

LanzaTech is a pioneering company in carbon recycling and biorefining, leveraging advanced biological and technological processes to convert waste carbon into valuable products. Their innovative approach contributes significantly to reducing carbon emissions and promoting a circular economy. ## Technology and Process LanzaTech's core technology is gas fermentation, which uses proprietary microbes to consume carbon emissions from various industrial sources. This process converts carbon-rich gases into ethanol and other chemical building blocks, which can be further transformed into fuels, packaging materials, cosmetics, cleaning products, and textiles. ## Commercial Operations Operating at commercial scale since 2018, LanzaTech has multiple facilities worldwide. Three ethanol plants in China, utilizing emissions from steel mills and ferroalloy plants, have already diverted over 190,000 tonnes of CO2 emissions into valuable products. The company aims to have 20 plants operational by the end of 2024. ## Carbon Abatement and Production LanzaTech's facilities boast significant carbon abatement and ethanol production capacities. Their annual CO2 abatement capacity exceeds 500,000 metric tons, while their annual ethanol production capacity surpasses 300,000 metric tons. ## Partnerships and Global Presence The company collaborates with major consumer brands like Zara, Coty, and Lululemon to produce sustainable products. LanzaTech's corporate headquarters and R&D facilities are in Chicago, USA, with operations and business offices in China and India. ## Funding and Milestones LanzaTech has secured $250 million in funding and holds a robust IP portfolio with over 750 patents (pending and granted). In 2022, it became the first Carbon Capture and Utilization (CCU) company to go public. ## Research and Development The company focuses on synthetic biology, fermentation, and analytical processes. LanzaTech has demonstrated feedstock flexibility, converting various waste streams into ethanol and other products, validated through multiple demonstration plants and pilot projects. LanzaTech's innovative approach to carbon recycling and biorefining positions it at the forefront of sustainable solutions for reducing carbon emissions and producing valuable products from waste carbon.

B

Borderless AI

Borderless AI is a cutting-edge startup revolutionizing global human resources (HR) and payroll management through advanced artificial intelligence (AI). Founded in 2022 by Willson Cross and Sean Aggarwal, the company is headquartered in Toronto, Canada. Borderless AI has raised $27 million in seed funding, led by Susquehanna and Aglaé Ventures. The company's flagship product is an AI agent named Alberni, designed specifically for the HR industry. Alberni leverages generative AI and conversational AI to automate and expedite processes such as onboarding, managing, and paying international team members. Key features of Alberni include: - Global Compliance: Provides real-time, accurate compliance information across over 170 countries. - Multilingual Support: Fluent in over 100 languages, enabling effective cross-language communication. - Automated Processes: Streamlines tasks like contract creation, expense management, and payroll set-up. - Advanced Retrieval-Augmented Generation (RAG): Enhances accuracy and responsiveness in answering user queries. Borderless AI offers services such as: - Employer of Record (EOR) Services: Enables businesses to hire and pay employees internationally without establishing foreign entities. - Global Contractor Management: Includes localized benefits and visa/immigration support. - Free Access to Alberni: Offers HR features like international expense reimbursements and AI-generated employment agreements at no cost. The company has a strategic partnership with Cohere, a leader in Large Language Models (LLMs), to enhance Alberni's capabilities. Borderless AI's mission is to bring economic empowerment by removing geographic barriers and democratizing access to global job opportunities, while simplifying the global HR stack and ensuring compliance.